Bioniche Life Sciences Inc. To Report Third Quarter Results For Fiscal 2006

BELLEVILLE, Ontario, May 2 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company , will be announcing financial results for the third quarter of its 2006 fiscal year through a:

Conference Call & Audio Web Cast Tuesday, May 9, 2006 10:00 a.m. (EDT)

To participate in the conference call, please phone (416) 644-3433 (Toronto area) or toll-free 1-800-796-7558. A listen-only audio web cast will be available at the following locations:

http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=1464540 (English) http://www.cnw.ca/fr/webcast/viewEvent.cgi?eventID=1464540 (French) or through the link on the home page of the Bioniche website (http://www.Bioniche.com)

A replay of the conference call will be available until May 16, 2006 by calling (416) 640-1917 or toll-free 1-877-289-8525 (passcode: 21186854#). The web cast will be available for replay using the above links until August 7, 2006.

A news release will be distributed prior to the conference call/web cast.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 185 skilled personnel and has three principal operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in these three segments. For more information, please visit http://www.Bioniche.com.

Except for historical information, this news release may contain forward- looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For further information, please contact: Jennifer Shea Manager of Corporate Communications & Investor Relations Bioniche Life Sciences Inc. Telephone: (613) 966-8058 ext. 1250 Cell: (613) 391-2097

Audio: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=1464540http://www.cnw.ca/fr/webcast/viewEvent.cgi?eventID=1464540Bioniche Life Sciences Inc.

CONTACT: Jennifer Shea, Manager of Corporate Communications & InvestorRelations, Bioniche Life Sciences Inc., +1-613-966-8058, ext. 1250, Cell:+1-613-391-2097

Back to news